Madho Sharma
Pulmonary Disease · Edison, NJNPI 1134111883
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,088 and has fallen 50.4% since, to $540 in 2025.
Across 93 payments — averaging $41.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$635
- Vital Connect, Inc$387
- Johnson & Johnson$376
- Novo Nordisk$288
- Boehringer Ingelheim$278
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$215
- plus $2K from 16 others
What the payments were for
- Food & beverage$3,846100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 23 | $635 |
| Vital Connect, Inc | 4 | $387 |
| Johnson & Johnson | 3 | $376 |
| Novo Nordisk | 5 | $288 |
| Boehringer Ingelheim | 4 | $278 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $215 |
| Lilly USA, LLC | 8 | $165 |
| Heartflow, Inc. | 1 | $148 |
| Novartis | 1 | $137 |
| Cvrx, Inc. | 1 | $135 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Abbott | 1 | $124 |
| Phathom Pharmaceuticals, Inc. | 1 | $121 |
| E.r. Squibb & Sons, L.L.C. | 1 | $105 |
| Scpharmaceuticals Inc. | 1 | $104 |
| Amgen | 1 | $104 |
| Amarin Pharma, Inc. | 7 | $95 |
| AstraZeneca | 7 | $92 |
| Pfizer | 3 | $43 |
| Sanofi | 2 | $29 |
| QOL Medical, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$376
- AREXVY$250
- RYBELSUS$250
- JARDIANCE$250
- VITALPATCH RTM$212
- FFRct$148
- LEQVIO$137
- Barostim Neo System$135
- Inpefa$125
- TRELEGY ELLIPTA$125
- PRALUENT$125
- AVEIR$124
- VOQUEZNA$121
- FUROSCIX$104
- Repatha$104
How this compares
$3,846 in reported general payments places this provider in the 60th percentile of 472 pulmonary disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 16 | $447 |
| ClopidogrelClopidogrel Bisulfate | 14 | $437 |
| Rosuvastatin Calcium | 20 | $339 |
| Atorvastatin Calcium | 20 | $268 |
| Amlodipine Besylate | 17 | $238 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $138 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Edison
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.